PK and DDI Study of D565 and D930 in Healthy Males

Phase 1, open-label, single-arm trial of latanoprost and dorzolamide in Glaucoma and ocular hypertension, sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve over the dosing interval at steady state for D930 at 24 hours and Maximum Plasma Concentration at steady state for D930 at 24 hours. Started Feb 2017; status: completed.